TP53 and non-small cell lung carcinoma: At present, to this clinical condition, combinations with immunotherapy or combination therapies of EGFR-TKIs and antiangiogenic agents may be valuable options for the advanced NSCLC patients with EGFR/TP53 co-mutation.